Try our Advanced Search for more refined results

Nixed Pfizer Inversion Casts Uncertainty On Similar Deals

By Chelsea Naso (April 6, 2016, 7:52 PM EDT) -- Pfizer's scrapped plans for its record $160 billion corporate inversion with Irish drugmaker Allergan may be just one casualty of the U.S. Department of Treasury's latest rulemaking, but the thwarted deal is fostering concerns that other pending inversions will also be scuttled by the government's hard stance on the deal structure....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!